

EDITORIAL COMMENT

CMR-Derived Regional Strain and Radiation-Induced Cardiotoxicity



The Importance of Myocardial Inflammation*

Giselle C. Meléndez, MD

Radiation therapy (RT) is used in more than 50% of all cancer patients and it is a critical component of treatment regimens for Hodgkin's lymphomas, and lung and breast cancers. Even though contemporary techniques use strategies to improve RT delivery, and methods to minimize ionizing radiation exposure to tumor-adjacent tissues without jeopardizing treatment efficacy, cardiac tissue damage is frequently unavoidable (1). Consequently, RT has been consistently associated with cardiovascular morbidity and mortality due to coronary artery disease, valvular heart disease, pericarditis, and cardiomyopathy associated with diffuse fibrosis and arrhythmias (2). Although left ventricular (LV) dysfunction and cardiotoxicity are uncommon findings early after RT, preclinical studies have shown that myocardial tissue damage does occur and, if left untreated, may progress to heart failure (3). There is growing interest in the assessment of LV function by echocardiography-derived global longitudinal strain as a strategy to detect early cardiotoxicity due to its high sensitivity and reproducibility. Strain may also be important in defining cancer therapy-related cardiac dysfunction (CTRCD) prognosis and the role of cardioprotective therapy (4,5). However, cardiovascular magnetic resonance (CMR)-

derived strain is also highly accurate and has the additional benefit of a unique ability to identify sub-clinical pathological changes of the myocardial tissue through novel mapping techniques. T1 and T2 mapping relaxation times become prolonged in the presence of myocardial tissue injury and edema, respectively (6).

In this issue of *JACC: CardioOncology*, Ibrahim et al. (7) present a novel preclinical study in which they explore the utility of CMR imaging to assess LV function and use tissue characterization techniques to establish early imaging markers of RT injury and their association with myocardial histopathological as well as cellular changes. These investigators used an inbred salt-sensitive rat strain that has been previously shown by the authors to be a reproducible model of cardiac tissue injury induced by a high single dose of RT (24 Gy) (8,9). CMR-derived LV volumes, and circumferential, radial, and longitudinal strains as well as T1/T2 maps were acquired 8 and 10 weeks after RT and compared to nonirradiated animals. Subsequently, cardiac tissue was examined to assess interstitial fibrosis, cardiomyocyte vacuolation and necrosis, and inflammatory cell infiltration (mast cells). The authors make several important observations. First, the mean LV ejection fraction increased by 11 and 12 percentage points at 8 and 10 weeks post-RT, respectively, when compared to nonirradiated animals. This was accompanied by an increase in LV mass. Interestingly and despite a preserved LV ejection fraction and a compensatory increase in LV wall thickness, global circumferential strain worsened at these time points and lateral segments of the myocardium were more severely affected. These subacute abnormalities in strain corresponded with a ~27% increase in T2 relaxation times at 8 weeks which slightly decreased by

*Editorials published in *JACC: CardioOncology* reflect the views of the authors and do not necessarily represent the views of *JACC: CardioOncology* or the American College of Cardiology.

From the Departments of Internal Medicine, Section on Cardiovascular Medicine, and Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

The author attests they are in compliance with human studies committees and animal welfare regulations of the author's institution and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

10 weeks post-RT, but remained elevated compared to nonirradiated rats. Both global circumferential strain and T2 were associated with post-necropsy qualitative assessment of myocardial necrosis and vacuolation, denoting myocardial edema (10), particularly in the lateral wall where strain was more compromised. Interestingly, the investigators observed a decrease in capillary density along with an increase of mast cell infiltration; prior studies suggest that mast cells are protective against RT myocardial injury (11). However, strong experimental evidence in other models of heart failure suggests that mast cells play a critical role in the fibrotic remodeling of the cardiac extracellular matrix by the production and release of cytokines and growth factors that enhance excess matrix deposition (12). In this study, interstitial fibrosis measured by T1 mapping and histopathology (diffuse and perivascular fibrosis) were unchanged after RT. It is possible that inflammatory cell recruitment precedes the initiation of cardiac fibrotic remodeling. Importantly, these observations raise the provoking question of whether modulation of inflammation may thwart the progression of adverse LV remodeling induced by RT. These findings underscore the complexity of the pathophysiology of myocardial remodeling induced by cancer therapies.

Although it seems clear by the findings reported here that segmental strain deterioration and T2 prolongation are early imaging biomarkers, it remains to be determined if these early changes forecast the development of CRTCD. Furthermore, the complexity of RT in clinical practice limits the interpretation and translation of the results. First, it is important to recognize that the rats in this study received 1 relatively large dose of whole heart radiation that does not resemble the typical fractionated scheme of RT used in humans. Second, the study used healthy adult rats that fail to account for pre-existing

cardiovascular risk factors (e.g., coronary artery disease, hypertension, and obesity) or more vulnerable populations such as pediatric and elderly cancer patients. Similarly, an important factor that significantly increases the risk of CRTCD after RT is the use of concomitant cardiotoxic cancer therapies such as chemotherapy and targeted therapies. Third, because CMRs were performed on a 9.4-T scanner, it remains uncertain whether the changes in imaging biomarkers in small animals, especially regional differences, can be detected using clinical 1.5-T and 3-T field strengths, in addition to the lack of standardized analysis protocols, and variability across different vendors.

In summary, efforts such as those reported here conducted by a team of clinicians and scientists continue to be essential and should be encouraged. Ibrahim et al. (7) have shown that CMR-derived segmental strain incorporating tissue characterization techniques are useful to identify subclinical myocardial injury. Most importantly, the implications of this report suggest that future investigations should be directed toward successfully translating the finding into clinical practice to improve the surveillance and prevention of cardiotoxicity in cancer patients undergoing RT.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Financial support was provided in part by National Institutes of Health grant K01HL145329. The author has reported that she has no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr. Giselle C. Meléndez, Internal Medicine/Cardiovascular Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA. E-mail: gmelende@wakehealth.edu. Twitter: [@gmelendezMD](https://twitter.com/gmelendezMD).

REFERENCES

1. Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. *Int J Radiat Oncol Biol Phys* 2010;76:656-65.
2. Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-associated cardiac disease: a practical approach to diagnosis and management. *J Am Coll Cardiol Img* 2018;11:1132-49.
3. Schwebe M, Ameling S, Hammer E, et al. Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. *Biochem Pharmacol* 2015;94:109-29.
4. Houbois CP, Nolan M, Somerset E, et al. Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography. *J Am Coll Cardiol Img* 2020 Nov 25 [E-pub ahead of print].
5. Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2020;22:1504-24.
6. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. *Nat Rev Cardiol* 2015;12:18-29.
7. Ibrahim E-SH, Baruah D, Croisille P, et al. Cardiac magnetic resonance for early detection of radiation therapy-induced cardiotoxicity in a small

animal model. *J Am Coll Cardiol CardioOnc* 2021;3:113-30.

8. Schlaak RA, Frei A, Schottstaedt AM, et al. Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. *Am J Physiol Heart Circ Physiol* 2019;316:H1267-80.

9. Schlaak RA, SenthilKumar G, Boerma M, Bergom C. Advances in preclinical research models

of radiation-induced cardiac toxicity. *Cancers (Basel)* 2020;12:415.

10. Galan-Arriola C, Lobo M, Vilchez-Tschischke JP, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. *J Am Coll Cardiol* 2019;73:779-91.

11. Boerma M, Wang J, Wondergem J, et al. Influence of mast cells on structural and functional

manifestations of radiation-induced heart disease. *Cancer Res* 2005;65:3100-7.

12. Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. *Cardiovasc Res* 2011;89:12-9.

KEY WORDS cardiotoxicity, inflammation, left ventricular strain, radiation therapy